SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 13, 2016

 

 

INTERNATIONAL STEM CELL CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-51891   20-4494098

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

5950 Priestly Drive, Carlsbad, CA 92008

(Address of principal executive offices, including zip code)

(760) 940-6383

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CAR 240.13e-4(c))

 

 

 


Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Following approval by the stockholders at the 2016 Annual Meeting, as discussed below, on May 13, 2016, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Certificate of Incorporation, as amended, reducing the authorized number of shares of common stock to 120,000,000.

 

Item 5.07 Submission of Matters to a Vote of Security Holders

The Company held its Annual Meeting of Stockholders on May 13, 2016. The stockholders considered five proposals, each of which is described in more detail in the Company’s definitive proxy statement dated April 18, 2016.

 

Proposal 1:

   Election of five directors to hold office until the 2017 Annual Meeting:

 

  A. Directors elected by holders of Series D Preferred Stock.

 

     FOR      WITHHELD  

Andrey Semechkin

     2,457,142         0  

Russell Kern

     2,457,142         0  

 

  B. Directors elected by holders of all shares of stock.

 

     FOR      WITHHELD  

Donald A. Wright

     4,114,985        19,788  

Paul V. Maier

     4,114,906        19,867   

Charles J. Casamento

     4,114,737        21,036  

Broker Non-Votes: 1,611,146

All of the foregoing candidates were elected.

 

Proposal 2:    Ratification of the selection of Mayer Hoffman McCann, P.C., as the Company’s independent public accountants for the Company’s fiscal year ending December 31, 2016 (shares of common stock and all classes of preferred stock voting together):

 

FOR

 

AGAINST

 

ABSTAIN

5,241,594

  50,028   26,536

Broker Non-Votes: none

The foregoing proposal was approved.

 

Proposal 3:

   Approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement (shares of common stock and all classes of preferred stock voting together):

 

FOR

 

AGAINST

 

ABSTAIN

4,084,389

  36,296   13,980


Broker Non-Votes: 1,611,254

The foregoing proposal was approved.

 

Proposal 4: Approval of the amendment to the Company’s Certificate of Incorporation to decrease the number of authorized shares of Common Stock to 120,000,000 (shares of common stock and all classes of preferred stock voting together):

 

FOR

 

AGAINST

 

ABSTAIN

5,184,978

  122,764   10,412

Broker Non-Votes: 427,765

The foregoing proposal was approved.

 

Proposal 5: Approval of amendments to the Company’s 2010 Equity Participation Plan (shares of common stock and all classes of preferred stock voting together):

 

FOR

 

AGAINST

 

ABSTAIN

4,069,235

  47,900   17,531

Broker Non-Votes: 1,611,253

The foregoing proposal was approved.

 

Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

 

Exhibit
No.

  

Description

3.1    Form of Certificate of Amendment to Certificate of Incorporation.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

International Stem Cell Corporation
By:  

/s/ Mahnaz Ebrahimi

  Mahnaz Ebrahimi
  Chief Financial Officer

Dated: May 17, 2016

Exhibit 3.1

CERTIFICATE OF AMENDMENT

TO THE CERTIFICATE OF INCORPORATION OF

INTERNATIONAL STEM CELL CORPORATION

International Stem Cell Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify:

FIRST: On March 24, 2016, the Board of Directors of the Corporation duly adopted resolutions approving the following amendment to the Corporation’s Certificate of Incorporation (the “Certificate of Incorporation”), declaring said amendment to be advisable and providing for the consideration of such amendment at the annual meeting of stockholders of the Corporation.

SECOND: On May 13, 2016, the annual meeting of stockholders of the Corporation was duly called and held, upon notice in accordance with Section 222 of the General Corporation Law of the State of Delaware, at which meeting the necessary number of shares required by statute were voted in favor of the amendment.

THIRD: Said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

FOURTH: Section 1 of Article FOURTH of the Certificate of Incorporation is hereby amended and restated to read in its entirety as follows:

“Section 1. Authorization of Shares.

The aggregate number of shares of capital stock which the Corporation will have the authority to issue is 140,000,000 shares, consisting of 120,000,000 shares of common stock, having a par value of $0.001 per share (“Common Stock”), and 20,000,000 shares of preferred stock, having a par value of $0.001 per share (“Preferred Stock”).”

IN WITNESS WHEREOF, International Stem Cell Corporation has caused this Certificate of Amendment to be signed by the undersigned, thereunto duly appointed, this 13th day of May, 2016.

 

By:  

 

Mahnaz Ebrahimi

Chief Financial Officer and Secretary